Next Article in Journal
Yeast Smell Like What They Eat: Analysis of Volatile Organic Compounds of Malassezia furfur in Growth Media Supplemented with Different Lipids
Previous Article in Journal
Determination of Selected Priority Pesticides in High Water Fruits and Vegetables by Modified QuEChERS and GC-ECD with GC-MS/MS Confirmation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 3
10.3390/molecules24030418
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders

by
Priyanka Dhiman
1,
Neelam Malik
1,
Eduardo Sobarzo-Sánchez
2,3,*,
Eugenio Uriarte
4,5 and
Anurag Khatkar
1,*
1
Faculty of Pharmaceutical Sciences, M. D. University, Rohtak 124001, India
2
Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida, 15782 Santiago de Compostela, Spain
3
Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8370178 Santiago, Chile
4
Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain
5
Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile, 7500912 Santiago, Chile
*
Authors to whom correspondence should be addressed.
Molecules 2019, 24(3), 418; https://doi.org/10.3390/molecules24030418
Submission received: 30 November 2018 / Revised: 21 January 2019 / Accepted: 22 January 2019 / Published: 24 January 2019
(This article belongs to the Section Natural Products Chemistry)
Browse Figures
Versions Notes

Abstract

:
Monoamine oxidase inhibitions are considered as important targets for the treatment of depression, anxiety, and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. This has encouraged many medicinal chemistry research groups for the development of most promising selective monoamine oxidase (MAO) inhibitors. A large number of plant isolates also reported for significant MAO inhibition potential in recent years. Differently substituted flavonoids have been prepared and investigated as MAO-A and MAO-B inhibitors. Flavonoid scaffold showed notable antidepressant and neuroprotective properties as revealed by various and established preclinical trials. The current review made an attempt to summarizing and critically evaluating the new findings on the quercetin and related flavonoid derivatives functions as potent MAO isoform inhibitors.

Graphical Abstract

1. Introduction

Depression and anxiety are estimated as incapacitating mental disorders which impose a huge health burden globally. According to the World Health Organization, major depression has now recognized as the fourth extensive cause of the worldwide in incapacity balanced life-years and could eventually turn into the second most critical cause by 2020 [1,2,3]. Treatment and therapies for mental disorder are also not economical. In the United States, the expenses of depression treatment and the costs experienced by less research work rate is estimated at more than $44 billion in 1990, which currently raised many fold [4,5]. Hence, the research for the discovery of potent and safe anti-depressant agents has attained importance due to a high mortality ratio of depressive disorders and their contribution for the destruction of other routine physiological processes.
Moreover, neurodegenerative disorders constitute the third most essential health issue in different developed countries. Alzheimer’s disease is the most widely recognized neurodegenerative disorder followed by Parkinson’s disease. Along with the aging problem of human society, Alzheimer’s disease (AD) has become one of the biggest threats to the modernize population. Alzheimer’s disease is indicated by nerve cells die in the cerebral cortex and accounts for 60 to 80 percent of dementia cases which affected more than 25 million people worldwide in 2000 and may eventually to increase to 114 million by 2050 [6,7,8,9]. General treatment of this disease is the utilization of dopaminergic agonists. Nonetheless, other medicinal options can be employed, like the utilization of specific monoamine oxidase B inhibitors, or the use of neuroprotective antioxidant agents to prevent the oxidative damage of neuronal cells. In the last few years, it has been proved that the overexpression of brain MAO-B also causes the neurodegeneration via generation hydroxyl radicals [10,11]. This certainty provokes an increase in free radical generation leads to oxidative stress, neuronal cell death and further the formation of the β-amyloid plaques [12].
The theory of MAO-B inhibitors for the prevention of neuronal damage is also accepted due to the reduction of hydrogen peroxide formation through inhibition of MAO. Clinical data suggests that patients with major depression have symptoms that are reflected changes in brain monoamine neurotransmitters, specifically serotonin (5-HT) and norepinephrine (NE) [13,14,15]. As per the most accepted hypothesis of depression, including the monoamine theory, dopamine (DA) is also implicated in the pathophysiology of various neurological disorders. Inhibitors of the enzyme monoamine oxidase were the first clinically used antidepressants; however, their utilization has reduced due to their documented serious adverse effects, their drug and food interactions, and the discovery of other target proteins [16,17,18,19]. Moreover, reports of hypertensive crises, liver toxicity, and hemorrhages and in some cases death resulted in the withdrawal of many MAO inhibitors from the market. Since then, medicinal chemists have been continuously involved in developing novel lead compounds that can selectively inhibit single isoform of MAO and can act as an effective therapeutic agent for various mental and neurological disorders [20,21,22].
Monoamine oxidase (MAO; EC 1.4.3.4) is a flavin adenine dinucleotide (FAD) dependent enzyme which is mainly localized on the outer mitochondrial membrane, responsible for the oxidative deamination of monoamines, including neurotransmitters, such as norepinephrine, dopamine, and serotonin (5-hydroxytryptamine [5-HT]) [23,24]. The two isoforms of MAO exists MAO-A and MAO-B, which differ in amino acid sequence, susceptibility to specific inhibitors, substrate specificity, and tissue distribution [25]. MAO-A preferentially deaminates noradrenaline and serotonin (5-hydroxytryptamine), whereas MAO-B preferentially deaminates β-phenyl-ethylamine and benzylamine. Inside the brain, MAO-B is mainly localized in the glial cells, while MAO-A found in the extraneuronal compartment and inside the dopaminergic, serotonergic and noradrenergic nerve terminals [26].
The oxidative deamination catalyzed through MAO leads to the formation of hydrogen peroxide (H2O2) and different reactive oxygen species has sufficient deleterious reactivity which accounts for associated health-related problems including neurological damage. The generation of H2O2 via MAOs is also reported to be a cytotoxic factor involved in oxidative stress, causes degeneration of nigral cells in Parkinson’s disease [27,28].
The modern search in the anti-MAO field is now directed toward the hybrid compounds, the latent risks in bioavailability and safety is a big concern in their further development. Despite notable progress in understanding their isoforms with respect to their 3D-structures, functionality, inhibitors, and substrates, no general rules have been formulated for the rational design of efficient, selective and reversible MAO inhibitors [29,30]. The current review made an attempt to identify the MAO inhibition property of quercetin and related derivatives and establish the rational design of new MAOIs from this investigation.

2. Chemistry and Therapeutic Journey of Quercetin and Related Derivatives

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is the significant illustrative of flavonols, a subclass of flavonoids. Quercetin, a type of flavonoids called flavonols, has received significant consideration in view of its overwhelming existence in herbs and food [31,32]. The major sources of quercetin are fruits such as citrus, apples, cherries and berries, vegetables such as broccoli, onions, and beverages such as red wine and tea. Moreover, it has been likewise found in several therapeutic plants, for example, Aesculus hippocastanum, Ginkgo biloba, and Hypericum perforatum. Research interest for this flavonol derivative is because of its diverse range of biological properties [33,34].
Quercetin not only shows antioxidant activity like other natural flavonols but is also reported to have antiviral, anti-inflammatory, and antibacterial activities [35,36,37]. The exact mechanism by which quercetin shows these impacts are not completely clear, but rather it is conceivable that distinctive biochemical procedures are included. This natural flavonol is generally exists in a glycosylated form with its corresponding sugar part, generally glucose. The glycosylation may occur at any of the five OH groups of the flavonol ring, the most widely recognized quercetin glycoside exhibits the sugar moiety and structures speak to 60–75% of flavonoid intake [38]. Before oral ingestion, quercetin glycosides undergo deglycosylation either by cytosolic β-glucosidase or lactase phlorizin hydrolase. Further, the absorbed aglycone part is conjugated through sulphation, glucuronidation, or methylation. However, the aglycones and associated conjugates can cross the blood-brain barrier. Quercetin consists of a fused ring system with a benzopyran associated with an aromatic ring and phenyl substituents (Figure 1) [39].
In a study by Hwang and coworkers raveled the two natural flavonoids from the methanolic root extract of Sophora flavecens. The outcomes of the study indicated the dose-dependent MAO inhibition by kushenol F and formononetin with IC50 values of 69.9 and 13.2 µM, respectively (Figure 2). Interestingly, kushenol F mainly inhibited the MAO-B than MAO-A isoform shown the IC50 values of 63.1 and 103.7 µM, respectively. However, formononetin exhibited potential inhibitory effect towards MAO-B (IC50:11.0 µM) than MAO-A (IC50:21.2 µM) [40].
In 2010 Samoylenko and coworkers screened Banisteriopsis caapi (Malpighiaceae) constituents for the MAO inhibitory and antioxidative potential (found in South American liana of the family Malpighiaceae, B caapi is known to contain β-carboline alkaloids) [41]. Activity-guided fractionation of aqueous extract of B. caapi stems on led to the isolation of two popular proanthocyanidins (−)-procyanidin B2 and (−)-epicatechin (Figure 3). Epicatechin and (−)-procyanidin B2 showed considerable MAO-B inhibitory activity with IC50 66 and 36 µM, respectively and very weak MAO-A inhibitory potential with IC50 8.5 and 51.7 µM for procyanidin B2 and (−)-epicatechin, respectively. In addition, these components exhibited good antioxidant potential; both found to be more effective than standard antioxidants, vitamin C (IC50 < 0.14 and 0.58 µg/mL vs. 1.35 µg/mL), while (−)-epicatechin was found to be more active than Trolox (IC50 0.14 µg/mL).
In another study, the flavan-3-ols (−)-epicatechin and (+)-catechin were isolated from the hook extract of Uncaria rhynchophylla (Miq.) Jacks. using bioguided assay was found to inhibit MAO-B with the IC50 values of 57.9 and 88.9 µM, respectively, while the standard MAO-B inhibitor deprenyl showed an IC50 value of 0.3 µM [42]. (U. rhynchophylla (Rubiaceae), also known as cat’s claw herb, is a rhynchophylline plant species utilized in conventional Chinese medication). Lee et al., isolated flavonoids from 80% watery ethanol concentrate of entire plant of Artemisia vulgaris (Mugwort), and their structures were confirmed by utilizing different spectroscopic techniques. These compounds were recognized as jaceosidin, eupafolin, luteolin, quercetin, apigenin, aesculetin, esculetin-6-methylether, and scopoletin and were appeared to inhibit MAO with the IC50 estimations of 19.0, 25.0, 18.5, 72.9, 12.5, 1.0, 31.1, 32.2, and 45.0 µmol, respectively (Figure 4) [43].
Conversely, Kim and coworkers isolated a flavonoid, cynaroside from Angelica keiskei Koidzumi (A. keiskei K.). Cynaroside showed notable MAO inhibition with IC50 values MAO-A400 µM and MAO-B 268 µM. Therefore, it is likely that that inhibition of MAO-B exerts antidepressant activity (Figure 5) [44].
Another study by in 2000 by Pan and coworkers showed the MAO inhibition of isoliquiritigenin and liquiritigenin isolated from the methanolic extract of the flowering plant Sinofranchetia chinensis (Lardizabalaceae) was studied on rodent monoamine oxidase A and B [45]. MAO inhibitory activity was assessed radiochemically by using [14C] β-phenylethylamine (beta-PEA) and [14C]5-hydroxytryptamine (5-HT) as MAO-B or -A specific radio labeled substrates, respectively. Isoliquiritigenin and liquiritigenin acted as the potent MAO inhibitors against both MAO-B and -A in a dose-dependent manner (Figure 6). The MAO inhibitory IC50 values were calculated for isoliquiritigenin and liquiritigenin were 14 (12.8–15.6) and 32 (26–36) µmol/L for MAO-A isoform, 47.2 (39.5–54.5) and104.6 (89.0–118.9) µmol/L for MAO-B isoform, respectively.
Monoamine oxidase B inhibitory and free radical scavenging activities were evaluated for quercetin, rutin, isoquercitrin, and quercitrin, from the leave isolates of the Melastoma candidum (Melastomataceae) D. Don. using bioassay-guided fractionation (Figure 7) [46]. Melastoma candidum is a Chinese herb reported to clean heat and toxins, activating the blood and eliminating stasis, actuating the blood and wiping out stasis, for treating traumatic wounds, and for enacting fundamental vitality. The IC50 estimation of the four natural flavonoids, quercetin, rutin, isoquercitrin, and quercitrin on MAO-B was found ass 10.89, 3.89, 11.64, and 19.06 µM and analysis of enzyme kinetics calculated apparent inhibition constants (Ki) of 7.95, 1.83, 2.72, and 21.01 µM, respectively.
The in-vitro MAO inhibition by leaf extract of Ginkgo Biloba was carried out on mouse brain or liver monoamine oxidase (MAO)-A and -B activity [47]. The flavones apigenin and chrysin and the flavonols kaempferol and quercetin were extracted from a validated Gingko biloba preparation by reverse-phase HPLC system. All isolated flavonoid derivatives were observed as selective MAO-A inhibitors with the IC50 estimations of quercetin (4 µM), apigenin (2 µM), kaempferol (0.8 µM), and chrysin (1 µM). In the same assay phenelzine (irreversible and non-selective inhibitor of MAO) was taken as a reference compound (IC50 value 0.05 µM).
Quercetin was isolated from the methanolic extract of heather (Calluna vulgaris (L.) Hull–Ericaceae) and was evaluated for MAO inhibition [48]. By exhibiting IC50 value of 18 µM quercetin was distinguished as a selective MAO-A inhibitor. However, clorgyline, an MAO-A selective inhibitor, showed an IC50 value of 0.2 µM in the same assay. Bio-guided fractionation of the Rhodiola rosea L. (Crassulaceae) prompted to the isolation of epigallocatechin gallate (EGCG) dimer (Figure 8) which was tested for MAO inhibition. It showed a sigmoidal dose-response curve for MAO-B with pIC50 of 4.74 µM, whereas l-deprenyl showed the pIC50 value of 7.24 for MAO-B inhibition [49].
Lee and coworkers isolated different structure analogues of myricetin galloylglycoside from leaves of Acacia confuse, namely myricetin 3-O-(3″-O-galloyl)-d-rhamnopyranoside (1), myricetin 3-O-(2″-O-galloyl)-d-rhamnopyranoside (2), 3-O-(3″-O-galloyl)-Drhamnopyranoside 7-methyl ether1(3), myricetin 3-O-(2″-O-galloyl)-d-rhamnopyranoside 7-methyl ether (4), myricetin 3-O-(2″, 3″-di-O-galloyl)-d-rhamnopyranoside (5) (Figure 9). All five derivatives were evaluated for (semicarbazide-sensitive amine oxidase) SSAO inhibition and they all showed considerable amine oxidase inhibitory activity. Notably, the gallic acid at R3 position plays an important role for both biological activities [50].
The neurological and neuroprotective properties of Melissa officinalis was also documented by Lopez and coworkers. They assessed MAO-A inhibitory potential of methanolic extract of Melissa officinalis the plant. The IC50 estimations for MAO-A by methanolic extract (19.3 ± 2.3) was found to be better than the aqueous extract (48.3 ± 5.7) [51]. The antidepressant action of Morinda citrifolia fruit extracts was evaluated by estimation of MAO inhibition studies [52]. The bioactivity-fractionation led two flavonoids, quercetin, and kaempferol. Bioassay of kaempferol (Figure 10) and quercetin, for MAO-A, calculated IC50 values of 3.15 M and 0.72 M, and 20.4 M and 31.7 M for MAO-B, respectively, selectivity indices for MAO-A shown as 28 and 10.
Isolation of kaempferol and apigenin flavonoids from Sophorae flos and demonstration of their strong MAO-A inhibitory effects over rat brain mitochondrial monoamine oxidase MAO-A with an IC50 estimation of 10, and 14 µM were carried out by Ryu and coworkers [53]. They concluded that both compounds do not preferentially inhibit MAO-B. Moreover, several other isoflavonoids were isolated from Glycine max. and screened. In which the genistein (Figure 11) selectively inhibited rat brain mitochondrial MAO-A with IC50 value of the 40 µM.
Naringenin (Figure 12) was collected from the ethanolic extract of Mentha aquatica L. via by bioactivity-guided fractionation on preparative TLC [54]. The MAO inhibitory IC50 values by naringenin were calculated as 340 ± 30 M for the homogenate of rat liver mitochondrial fraction, 288 ± 18 M was calculated for MAO-B and for MAO-A 955 ± 129 M. However the MAO inhibitory potential of was not more than quercetin.
5-Hydroxyflavanone and 2-methoxy-3-(1-dimethylallyl)-6a,10a-dihydrobenzo(1,2-c)chroman-6-one (Figure 13) were extracted from the dried bark methanolic concentrate of Gentiana lutea [55]. Monoamine oxidase activity was evaluated on rat brain mitochondria fraction. Compound 2-methoxy-3-(1-dimethylallyl)-6a,10a-dihydrobenzo(1,2-c)chroman-6-one specifically inhibited MAO-B isoform, whereas entire inhibition was observed at 9 µM. 5-hydroxyflavanone exhibited more affinity for MAO for MAO-B than MAO-A isoform. Enzyme kinetics for the MAO inhibition was carried out by Lineweaver-Burk plots and both compounds showed the reciprocal plot curves for MAO inhibition activities, where the concentration of substrate also found intersected to the ordinate. The apparent Ki values of compounds of 5-hydroxyflavanone and 2-methoxy-3-(1-dimethylallyl)-6a,10a-dihydrobenzo(1,2-c)chroman-6-one for MAO-B were calculated as 1.1 µM and 1.4 µM, respectively.
In another study MAO inhibition studies were performed on pure anthocyanidins and the MAO-A and MAO-B inhibitory IC50 values were calculated as for pelargonidin (28 µM and 45 µM), peonidin (41 µM and 25 µM), malvidin (32 µM and 20 µM), delphinidin (36 µM and 38 µM), cyanidin (31 µM and 33 µM), and petunidin (35 µM and 45 µM).
Furthermore, the various diglycosides and glycosides of the above- revealed anthocyanidins were also investigated for MAO inhibition with IC50 estimation of 30–120 µM against MAO-A and 32–247 µM against MAO-B [56].
Bioactivity-guided isolation of seven flavonoids from the methanolic extract of Cayratia japonica was carried out to evaluate MAO inhibitory potential [57]. The structures of the components were identified as apigenin, apigenin-7-O-β-d-glucuronopyranoside, quercetin, luteolin, (+)-dihydro-kaempferol (aromadendrin), (+)-dihydroquercetin (taxifolin), and luteolin-7-O-β-d-glucopyranoside. Among the all titled compounds, flavonol, quercetin as well as the flavones such as luteolin and apigenin showed potential MAO inhibitory effects with estimated IC50 values of 33.7 μM, 23.7 and 6.7 respectively. Furthermore, quercetin was found as most active MAO-A inhibitor (IC50 value: 1 μM) than MAO-B (IC50 value: 90 μM), whereas luteolin and apigenin also mainly inhibited MAO-A isoform (IC50 values: 5.0 and 1.0 μM, respectively) as compared with MAO-B (IC50 values: 60.0 and 13.0 μM, respectively). Moreover, the flavanonol derivatives, aromadendrin, and taxifolin exhibited poor inhibition (IC50 values: 152.9 μM and 155.1, respectively). The flavone glycosides, luteolin-7-O-β-d-glucopyranoside and apigenin-7-O-β-d-glucuronopyranoside exhibited less MAO inhibitory activity (IC50 values: 118.6 and 81.7 μM, respectively).
Fourteen types of herbal plants were evaluated for MAO-B inhibitory potential. The extracts of Chrysanthemum indicum, Sophora japonica, Artemisia Messer-Schmidtiana, Ericibe obtusifolis significantly inhibited the MAO-B enzyme. Among them, Chrysanthemi indicum was selected for fractionation and identification of its active components, which led some flavonoids as diosmetin, acacetin, apigenin, 5,7-dihydroxy chromone, luteolin, and eriodictyol. The MAO inhibitory IC50 values for 5,7-dihydroxy chromone and diosmetin were calculated as following: 2.50, 0.20, 2.10 µM respectively, while the other principles showed weak inhibition [58].
Isoflavone daidzein and its various analogs such as daidzin, ononin, 7-o-ω-carboxypentylflavone, 7-O-r-carboxyheptyldaidzein, 7-o-isopropyldaidzein, 7-o-dodecyldaidzein, 7-o-ω-carboxyheptyldaidzein, 7-o-ω-carboxyundecyldaidzein, 7-o-ω-hydroxyethyl-2-(2-oxyethyl) oxyethyldaidzein (Figure 14) were evaluated for MAO inhibition. It was concluded that presence of a free 4′-OH function on isoflavone ring and a straight 7-O-alkyl chain substitution, that has a terminal polar function such as -COOH, -OH, and -NH2 is crucial for MAO inhibition. Most preferable chain lengths for the MAO inhibition were 7-O-ω-hydroxy, 7-O-ω-carboxy, and 7-O-ω-amino substituent, were respectively [59].

3. Molecular Docking Studies of Quercetin and Related Flavonoid Derivatives

In 2006, Zhang et al. determined MAO inhibition of natural flavonoids by docking experiments. Docking methodologies revealed that the quercetin can thoroughly bind within the active site of the hMAO-B (with drug score of −61.5). Close inspection of the docking poses shown that the binding not only depends on the hydroxyl groups at 7th or 5th positions (that is equivalent to the positions 1st and 3rd in xanthone ring) but also on the OHs present at other positions (Table 1). Furthermore, the ring B in catechol seems very important which notably contributes for the binding, and could increase the MAO inhibiting capacity of quercetin. This special character of OH and ring B found unique as compared to xanthones, which do not require catechol for the better restricting association with MAO protein and can be justified to some degree by the more adaptability of flavonoids than xanthones. This may because of the ring B in flavonoids that is rotatable through C2-C10 bond, through so the flavonoids modify their conformational changes to tie inside the dynamic locales of MAO proteins, pictured by the superimposed quercetin adaptations in the coupling pocket of MAO-B [60].
The methanolic extract from leaves of Hypericum hircinum showed monoamine oxidases (MAO) inhibition. The bioactivity guided isolation prompted to the isolation of quercetin and five different components, recognized for the first time from H. hircinum [67]. Quercetin was the main compound with a specific inhibitory action against MAO-A, with an IC50 estimation of 0.010 µM. To illustrate the behavioral impacts of quercetin the in-vivo animal study on mice was performed using the forced swimming test. The mechanism of inhibition was further confirmed by molecular docking studies by applying the graphical user interface by MacroModel (Maestro GUI), Schrodinger [61]. The interaction energy has shown a good correlation between the exploratory inhibition information and affirmed the particular MAO-A recognition in both configurationally ensembles calculated along with molecular docking and full energy minimization. The authors observed that quercetin associated well within the hMAO-A binding site than in the hMAO-B binding site due to the formation of maximum π-π interaction and intermolecular hydrogen bonds. Moreover Greeson and coauthors also discussed the pharmacological, toxicological, and clinical aspects on MAO inhibitory action of St. John’s wort (Hypericum perforatum) [62]. Design of the 3-(4-methoxyphenyl)-1H-benzo[f]chromen-1-one (Figure 15) was carried out MAO-A inhibitor PDB code (2Z5X) by in-silico techniques [68]. The strategy for the design was to modify the flavanone (C6-C3-C6 three ring skeleton) to benzoflavanone composes naphthalene in spite of the first C6 ring. The binding of this compound with MAO-A was investigated by molecular docking by FlexX program [69]. Visual inspection of the docking poses indicated four more residues, Tyr69, Gly67, Gly443, and Met350 in the complex of 3-(4-methoxyphenyl)-1H-benzo[f]chromen-1-one with MAOA. Moreover, 31 hydrophobic inactions were established with the MAO-A binding cavity.
A series of homoisoflavonoids 3-benzyl-4H-chromen-4-ones, 3-benzylchroman-4-ones, and have been synthesized and benzylidenechroman-4-ones was investigated for in vitro as inhibition of h-MAOA and h-MAOB by Desideri et al. [70]. Rationalized docking studies provided the inhibitory affinity of homoisoflavonoids with respect to isoforms of hMAO-A PDB (2XFN) and hMAO-B PDB (2Z5Y). Visual inspection of the docking poses of the (E)-3-(4-(dimethylamino)benzylidene)chroman-4-one chromone (Figure 16) and (E)-5,7-dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one (Figure 17), chromanone rings were positioned near to the flavin ring of hMAO-A. Interestingly, most of the docked ligands exhibited the same kind of binding interactions. The only difference in MAO-A PDB (2Z5Y) binding interaction was due to the presence of a hydroxyl OH in the former analog that established a single hydrogen bond with N5 atom of FAD. Moreover, (E)-5,7-dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one, nearby the FAD cofactor, formed an exclusive bond with Tyr69. The (E)-3-(4-(dimethylamino)benzylidene)chroman-4-one was found to be involved in hydrophobic interactions with Tyr444 and Asn181.
Furthermore, Chimenti et al. [71] reported another series of synthetic flavanones, thioflavones, and flavones, analogs, active against both monoamine oxidase isoforms (MAO-A and -B). To visualize the binding mechanism of both isomers of (R)-2j and (S)-2j enantiomers, docking studies were carried out by the Glide with respect to both isoforms of hMAO [61]. The molecular modeling studies showed good correlations to the experimental results, and hence proved the conformational flexibility of both 3 dihydrochromen-4-one, 2-(4-fluorophenyl)-7-methyl-2 enantiomers to fit within the active site of both hMAO isoforms with characteristic affinity. The most active compound 2-(4-fluorophenyl)-7-methyl-2,3-dihydrochromen-4-one exhibited nanomolar the inhibitory potential as the racemate and was the most potent inhibitor in the two enantiomeric forms.
More recently Turkmenoglu et al. [72] evaluated the hMAO inhibitory activity of four flavonoids, isoscutellarein 7-O-[6′′′-O-acetyl-β-d-allopyranosyl-(1→2)]-6″-O-acetyl-β-d-gluco-pyranoside, xanthomicrol, isoscutellarein 7-O-[6′′′-O-acetyl-β-d-allopyranosyl-(1→2)]-β-d-gluco-pyranoside and salvigenin from Sideritis using recombinant hMAO isoenzymes. Docking experiments showed salvigenin as the most potent hMAO-A inhibitor by forming several van der Waals and electrostatic interactions within the active site of the hMAO-A where aromatic coumarin ring of the salvigenin established two π-π staking with TYR444 and TYR407 residues situated in the cavity. Moreover, the xanthomicrol has shown selective inhibitory interactions towards hMAO-A by forming five hydrogen bonds with the amino acids residues of the side chains of active site hMAO-A isoform (between the hydroxyl and GLY66, hydroxyl and ASN181, hydroxyl and LYS305 and methoxy and TYR444). The aromatic coumarine ring of xanthomicrol was observed sandwiched between the TYR407and TYR444 amino acid residues, which established two π-π interactions with TYR407 and formed a hydrophobic cage within the binding pocket. More relevant molecular binding interactions among the natural leads and hMAO the docked complexes were analyzed by 2-dimensional methods. The docking profile of the selected compounds is given in the (Table 2).
In a subsequent paper, Gao et al. [63] reported a magnificent in silico target fishing protocol based on mining of diverse database, molecular modeling, ligand similarity searching, structure-based pharmacophore searching and docking protocols together for searching new potential therapeutic anti-Parkinson agents. They concluded that the establishment of productive enzyme-inhibitor interaction behavior of top two ranked targets monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) from the seven selected protein targets as important targets for baicalein function by literature. For the study flavonoid, baicalein was isolated from the root extract of Scutellaria baicalensis Georgi. Docking calculations were carried out using Glide software for the comparison of binding energy of baicalein with the standard [61]. Two catecholic OH groups of baicalein showed hydrogen bonding with Leu167and Leu164, respectively. Moreover, a network of productive hydrophobic interactions also appeared between MAO-B and baicalein, which appreciably contributed to the binding interactions. Baicalein notably reduced the formation of intracellular NO (nitric oxide), reactive oxygen species, and extracellular NO, due to reduced cell death, exposure of NMDA (N-methyl-d-aspartic acid). It was noticed that NMDA receptor with generally low agreement score cannot be a valuable target for baicalein, having no inhibitory impact on [3H]MK-801 binding. The authors validated and developed a consensus scoring formula for ranking of the targets of a titled compound.
Sivaraman and coworkers performed docking calculations to rationalize the MAO inhibitory potency of luteolin, quercetin, kaempferol, and apigenin by using Auto Dock tools [64]. The binding free energy (ΔG) and inhibition constants (Ki) of the natural ligands were computed via the Lamarckian Genetic Algorithm (LGA) of AutoDock application. Perfect to good correlations were established between the experimental and calculated Ki values [73] (Table 3).
In a later work, Beula and coworkers [65] isolated 6-prenyl apigenin (Figure 18) from a methanolic extract of Achyranthes aspera seeds and computed molecular docking to get insight into the binding modes of 6-prenyl apigenin within the monoamine oxidase-A enzyme pocket. Molecular docking studies were carried out by using AutoDock [64], revealed 6-prenyl apigenin as a promising candidate for hMAO-A inhibition by exhibiting calculated inhibition constant of about 1.23 µM and docking score of −8.06. To understand the structural role of the isolated 6-prenyl apigenin the 3D structural was divided into three fragments so-called flavones skeleton, the phenolic group at the 2nd position of the nucleus and a distal side chain located at the 6th position. It is worthy to note that the π electrons of the hydroxyl groups were sandwiched between phenolic side chains of TYR407 and TYR 444 composed the ‘aromatic cage’ of the hydrophobic pocket of the enzyme. Furthermore, another π-π stacking interaction has appeared between flavone moiety and TRP 441 residue within the hMAO-A binding site.
More recently Zarmouh et al. [74] reported the MAO inhibitory activity of the natural prenylflavanones, genistein (GST) and bavachinin (BNN) from the ethanolic extract of Psoralea corylifolia seeds. Psoralea corylifolia is a medicinal plant widely documented for its antiaging properties. These two unique prenylflavanones selectively inhibited MAO-B enzyme with the highest potential. Docking methodologies predicted the binding affinity for both flavonoids, genistein (GST) and bavachinin (BNN). Zarmouh and coworkers further explored their earlier studies in 2015 [75], the flavanone bavachinin (BNN) and its other structural analog bavachin (BVN) from the seeds of Psoralea corylifolia L. for their human MAO inhibition. Docking studies were performed to validate the correct binding and mechanistic insight into docking poses depicted in (Table 4). The docking poses were analyzed with reference of the bound ligands of the crystal structures of human MAOB-2-(2-benzofuranyl)-2-imidazoline complex and human MAO-A-harmine complex.
The same group further studied the isoflavone genistein (GST) and its structural analog daidzein (DZ) as promising MAO-A and MAO-B inhibitors Zarmouh et al. [76]. Molecular docking studies of GST and DZ was performed within the binding pocket of MAO isoforms. In the case of the hMAO-B, both analogs chromone ring were docked entirely within the hydrophobic part of the binding site (substrate-binding domain). Due to their phenolic OH moiety near to the entrance cavity, both derivatives were positioned far from FAD and its surrounding tyrosine amino acid residues. The GST C4′-OH group moiety formed maximum hydrogen bonds far from the hydrophobic sites than DZ. This molecular network increased the reversibility due to not affecting the flavin structure and possessing reversible H-bond interactions and hydrophobic. In case of MAO-A, the chromone ring of two isoflavone ligands were positioned in the compact entrance cavity near the to the flavin cofactor (FAD), whereas their hydroxy-phenyl group was located to the hydrophobic active site entrance surfaces. Both isoflavones possessed crossed and similar orientation as compared with the standard. A best-matched docking pose of the standard was contributed by a slight pull of GST toward a hydrophilic zone at its C5-OH group. The docking studied observations are given in (Table 5).
Recently Gidaro and coworkers reported a computational method to generate the binding modes of quercetin and kaempferol to the active site of both hMAO isoforms [66]. All the lowest energy conformations were generated through the application of the OPLS-2005 force field, before docking simulations methods. Computation of free binding energy (ΔG Bind) for each docked complex was determined through Prime/MM-GBSA approach along with OPLS-2005 force field and the default parameters settings. Subsequently, quantum mechanics/molecular mechanics (QM/MM) docking calculations were carried out by the Schrödinger QM-Polarized Ligand Docking Protocol (QPLD) application [61]. Finally, results of molecular dynamic simulations established the specificity of the reversible inhibitors was mainly because of the structural shape and size of the substrate/inhibitor cavity, restricted by PHE208 and ILE335 amino acid residues within hMAOA, which correspond to ILE199 and TYR326 in hMAO-B. Binding mode of the kaempferol in the catalytic site of hMAO-A showed hydrophobic interactions with key residues of hMAO-A for a longer time than in the hMAO-B pocket. Kaempferol retained 90% of the simulation time with PHE208 and 80% of the total simulation time hydrophobic interactions with ILE335 of hMAO-A. Conversely, in the binding pocket of hMAO-B, kaempferol retained 80% simulation time with TYR326 and 30% of the simulation time through hydrophobic contacts with ILE199. The detailed description of docking analysis is given in (Table 6).

4. Conclusions

This deep exploration of the quercetin and related flavonoid derivatives highlights the enthusiasm of therapeutic science specialists towards finding new potent and selective monoamine oxidase inhibitors or useful targeting agents for neurological and mental disorders. The current review is aimed to demonstrate the tremendous pharmacological MAO inhibition profile of natural flavonoid derivatives. The experimental in vitro studies suggested that natural flavonoids showed micro- to nanomolar range IC50 values against both MAO isoforms. Furthermore, the docking studies correlated in many experiments to explore the molecular mechanism of flavonoid at the MAO receptor level. This may give the idea for the structural activity requirement of different classes of natural flavonoids for the MAO inhibition. Compilation of overall SAR studied indicated some characteristics of flavonoid moiety (Figure 19). The glycosylation with sugar reduces the hMAO inhibitory potential of flavonoid as studies by Lee and coworkers [50]. Moreover, the mono-substitution enhance the selectivity towards hMAO-A; di-substitution enhance selectivity towards hMAO-B as indicated by Chimenti and coworkers [71]. The unsturation of chromone ring is crucial for MAO inhibition. Nevertheless, Presence of OH group decrease the MAO inhibitory potential as observed by Turkmenoglu and coworkers [72]. Hence, the perditions of in vitro and in silico properties on flavonoid moiety could help to further modification and clinical exploration as flavonoid based potent MAO inhibitors.

Acknowledgments

Authors are thankful for the Library access provided by Maharshi Dayanand University, Rohtak, India.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Murray, C.J.; Lopez, A.D. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996, 274, 740–741. [Google Scholar] [CrossRef] [PubMed]
  2. Braga, R.J.; Mendlowicz, M.V.; Marrocos, R.P.; Figueira, I.L. Anxiety disorders in outpatients with schizophrenia: Prevalence and impact on the subjective quality of life. J. Psychiatry. Res. 2005, 39, 409–414. [Google Scholar] [CrossRef]
  3. Wilson, K.G.; Chochinov, H.M.; Skirko, M.G.; Allard, P.; Chary, S.; Gagnon, P.R.; Macmillan, K.; De Luca, M.; O’Shea, F.; Kuhl, D.; et al. Depression and anxiety disorders in palliative cancer care. J. Pain. Symptom. Manage. 2007, 33, 118–129. [Google Scholar] [CrossRef] [PubMed]
  4. Goldman, L.S.; Nielsen, N.H.; Champion, H.C. Awareness, diagnosis, and treatment of depression. J. Gen. Intern. Med. 1999, 14, 569–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Üstün, T.B.; Ayuso-Mateos, J.L.; Chatterji, S.; Mathers, C.; Murray, C.J. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry. 2004, 184, 386–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Kalaria, R.N.; Maestre, G.E.; Arizaga, R.; Friedland, R.P.; Galasko, D.; Hall, K.; Luchsinger, J.A.; Ogunniyi, A.; Perry, E.K.; Potocnik, F.; et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet. Neurol. 2008, 7, 812–826. [Google Scholar] [CrossRef]
  7. Bacho, M.; Coelho-Cerqueira, E.; Follmer, C.; Nabavi, S.M.; Rastrelli, L.; Uriarte, E.; Sobarzo-Sánchez, E. A medical approach to the monoamine oxidase inhibition by using 7H-benzo [e] perimidin-7-one derivatives. Curr. Top. Med. Chem. 2017, 17, 489–497. [Google Scholar] [CrossRef]
  8. Choi, D.Y.; Lee, Y.J.; Hong, J.T.; Lee, H.J. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res. Bull. 2012, 87, 144–153. [Google Scholar] [CrossRef]
  9. Javed, S.; Tariq, A.; Ahmed, T.; Budzyńska, B.; Tejada, S.; Daglia, M.; Nabavi, S.F.; Sobarzo-Sánchez, E.; Nabavi, S.M. Tanshinones and mental diseases: From chemistry to medicine. Rev. Neurosciences. 2016, 27, 777–791. [Google Scholar] [CrossRef]
  10. Joao Matos, M.; Viña, D.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Focusing on new monoamine oxidase inhibitors: Differently substituted coumarins as an interesting scaffold. Curr. Top. Med. Chem. 2012, 12, 2210–2239. [Google Scholar] [CrossRef]
  11. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potential of monoamine oxidase inhibitors. Nature. Rev. Neurosci. 2006, 7, 295–309. [Google Scholar] [CrossRef]
  12. Zheng, H.; Fridkin, M.; Youdim, M.B. From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. Mini. Rev. Med. Chem. 2012, 12, 364–370. [Google Scholar] [CrossRef] [PubMed]
  13. Carradori, S.; D’Ascenzio, M.; Chimenti, P.; Secci, D.; Bolasco, A. Selective MAO-B inhibitors: A lesson from natural products. Molec. Divers. 2014, 18, 219–243. [Google Scholar] [CrossRef] [PubMed]
  14. Fazel Nabavi, S.; Uriarte, E.; Rastrelli, L.; Modak, B.; Sobarzo-Sánchez, E. Aporphines and Parkinson’s Disease: Medical Tools for the Future. Curr. Top. Med. Chem. 2016, 16, 1906–1909. [Google Scholar] [CrossRef] [PubMed]
  15. Dhiman, P.; Malik, N.; Khatkar, A. 3D-QSAR and in-silico studies of natural products and related derivatives as monoamine oxidase inhibitors. Curr. Neuropharmacol. 2018, 16, 881–900. [Google Scholar] [CrossRef] [PubMed]
  16. Helguera, A.; Perez-Machado, G.; NDS Cordeiro, M.; Borges, F. Discovery of MAO-B inhibitors-present status and future directions part I: Oxygen heterocycles and analogs. Mini. Rev. Med. Chem. 2012, 12, 907–919. [Google Scholar] [CrossRef] [PubMed]
  17. Yanez, M.; Fernando Padin, J.; Alberto Arranz-Tagarro, J.; Camiña, M.; Laguna, R. History and therapeutic use of MAO-A inhibitors: A historical perspective of MAO-A inhibitors as antidepressant drug. Curr. Top. Med. Chem. 2012, 12, 2275–2282. [Google Scholar] [CrossRef]
  18. Blackwell, B.; Marley, E.; Price, J.; Taylor, D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br. J. Psychiatry. 1967, 113, 349–365. [Google Scholar] [CrossRef]
  19. Dhiman, P.; Malik, N.; Khatkar, A.; Kulharia, M. Antioxidant, Xanthine Oxidase and Monoamine Oxidase Inhibitory Potential of Coumarins: A. Review. Curr. Org. Chem. 2017, 21, 294–304. [Google Scholar] [CrossRef]
  20. Dhiman, P.; Malik, N.; Khatkar, A. Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential. Comb. Chem. High Throughput Screen. 2017, 20, 474–491. [Google Scholar] [CrossRef]
  21. McCabe-Sellers, B.J.; Staggs, C.G.; Bogle, M.L. Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy, and food industry converge. J. Food. Compost. Anal. 2006, 19, 58–65. [Google Scholar] [CrossRef]
  22. Rapaport, M.H. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: The state of the art. J. Clin. Psychiatry. 2007, 68, 42–46. [Google Scholar] [PubMed]
  23. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: From genes to behavior. Annu. Rev. Neurosci. 1999, 22, 197–198. [Google Scholar] [CrossRef]
  24. Ebadi, M.; Brown-Borg, H.; Ren, J.; Sharma, S.; Shavali, S.; El ReFaey, H.; Carlson, E.C. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug. Targets. 2006, 7, 1513–1529. [Google Scholar] [CrossRef] [PubMed]
  25. Kalgutkar, A.S.; Dalvie, D.K.; Castagnoli, N.; Taylor, T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 2001, 14, 1139–1162. [Google Scholar] [CrossRef] [PubMed]
  26. Carradori, S.; Silvestri, R. New Frontiers in Selective Human MAO-B Inhibitors: Miniperspective. J. Med. Chem. 2015, 58, 6717–6732. [Google Scholar] [CrossRef]
  27. Maurel, A.; Hernandez, C.; Kunduzova, O.; Bompart, G.; Cambon, C.; Parini, A.; Francés, B. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am. J. Physiol. Heart. Circ. Physiol. 2003, 284, 1460–1470. [Google Scholar] [CrossRef]
  28. Maker, H.S.; Weiss, C.; Silides, D.J.; Cohen, G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. neurochem. 1981, 36, 589–593. [Google Scholar] [CrossRef]
  29. Ji, H.F.; Zhang, H.Y. Multipotent natural agents to combat Alzheimer’s disease. Functional spectrum and structural features. Acta. Pharmacol. Sin. 2008, 29, 143–151. [Google Scholar] [CrossRef]
  30. Decker, M. Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond. Curr. Med. Chem. 2011, 18, 1464–1475. [Google Scholar] [CrossRef]
  31. Erlund, I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr. Res. 2004, 24, 851–874. [Google Scholar] [CrossRef]
  32. Nijveldt, R.J.; Van Nood, E.L.; Van Hoorn, D.E.; Boelens, P.G.; Van Norren, K.; Van Leeuwen, P.A. Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 2001, 74, 418–425. [Google Scholar] [CrossRef] [PubMed]
  33. Proteggente, A.R.; Pannala, A.S.; Paganga, G.; Buren, L.V.; Wagner, E.; Wiseman, S.; Put, F.V.; Dacombe, C.; Rice-Evans, C.A. The antioxidant activity of regularly consumed fruit and vegetables reflects their phenolic and Vitamin C composition. Free. Radic. Res. 2002, 36, 217–233. [Google Scholar] [CrossRef] [PubMed]
  34. Hirpara, K.V.; Aggarwal, P.; Mukherjee, A.J.; Joshi, N.; Burman, A.C. Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anticancer. Agents. Med. Chem. 2009, 9, 138–161. [Google Scholar] [CrossRef] [PubMed]
  35. Guardia, T.; Rotelli, A.E.; Juarez, A.O.; Pelzer, L.E. Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hesperidin on adjuvant arthritis in rat. II farmaco. 2001, 56, 683–687. [Google Scholar] [CrossRef]
  36. Bravo, A.; Anacona, J.R. Metal complexes of the flavonoid quercetin: Antibacterial properties. Transit. Metal. Chem. 2001, 26, 20–23. [Google Scholar] [CrossRef]
  37. Kaul, T.N.; Middleton, E.; Ogra, P.L. Antiviral effect of flavonoids on human viruses. J. Med. Virol. 1985, 15, 71–79. [Google Scholar] [CrossRef] [PubMed]
  38. Ververidis, F.; Trantas, E.; Douglas, C.; Vollmer, G.; Kretzschmar, G.; Panopoulos, N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health. Biotechnol. J. 2007, 2, 1214–1234. [Google Scholar] [CrossRef] [PubMed]
  39. Jäger, A.K.; Saaby, L. Flavonoids and the CNS. Molecules 2011, 16, 1471–1485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Hwang, J.S.; Lee, S.A.; Hong, S.S.; Lee, K.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Arch. Pharm. Res. 2005, 28, 190–194. [Google Scholar] [CrossRef] [PubMed]
  41. Samoylenko, V.; Rahman, M.M.; Tekwani, B.L.; Tripathi, L.M.; Wang, Y.H.; Khan, S.I.; Khan, I.A.; Miller, L.S.; Joshi, V.C.; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol. 2010, 127, 357–367. [Google Scholar] [CrossRef] [PubMed]
  42. Hou, W.C.; Lin, R.D.; Chen, C.T.; Lee, M.H. Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J. Ethnopharmacol. 2005, 100, 216–220. [Google Scholar] [CrossRef] [PubMed]
  43. Lee, S.J.; Chung, H.Y.; Lee, I.K.; Oh, S.U.; Yoo, I.D. Phenolics with inhibitory activity on mouse brain monoamine oxidase (MAO) from whole parts of Artemisia vulgaris L (Mugwort). Food. Sci. Biotechnol. 2000, 9, 179–182. [Google Scholar]
  44. Kim, J.H.; Son, Y.K.; Kim, G.H.; Hwang, K.H. Xanthoangelol and 4-hydroxyderricin are the major active principles of the inhibitory activities against monoamine oxidases on Angelica keiskei K. Biomol. Ther. 2013, 21, 234–235. [Google Scholar] [CrossRef]
  45. Pan, X.; Kong, L.D.; Zhang, Y.; Cheng, C.H.; Tan, R.X. In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Acta. Pharmacol. Sin. 2000, 21, 949–953. [Google Scholar]
  46. Lee, M.H.; Lin, R.D.; Shen, L.Y.; Yang, L.L.; Yen, K.Y.; Hou, W.C. Monoamine oxidase B and free radical scavenging activities of natural flavonoids in Melastoma candidum D. Don. J. Agric. Food Chem. 2001, 49, 5551–5555. [Google Scholar] [CrossRef]
  47. Sloley, B.D.; Urichuk, L.J.; Morley, P.; Durkin, J.; Shan, J.J.; Pang, P.K.; Coutts, R.T. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J. Pharm. Pharmacol. 2000, 52, 451–459. [Google Scholar] [CrossRef]
  48. Saaby, L.; Rasmussen, H.B.; Jäger, A.K. MAO-A inhibitory activity of quercetin from Calluna vulgaris (L.) Hull. J. Ethnopharmacol. 2009, 121, 178–181. [Google Scholar] [CrossRef]
  49. Van Diermen, D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A.; Hostettmann, K. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J. Ethnopharmacol. 2009, 122, 397–401. [Google Scholar] [CrossRef]
  50. Lee, T.H.; Liu, D.Z.; Hsu, F.L.; Wu, W.C.; Hou, W.C. Structure-activity relationships of five myricetin galloylglycosides from leaves of Acacia confusa. Bot. Stud. 2006, 47, 37–43. [Google Scholar]
  51. López, V.; Martín, S.; Gómez-Serranillos, M.P.; Carretero, M.E.; Jäger, A.K.; Calvo, M.I. Neuroprotective and neurological properties of Melissa officinalis. Neurochem. Res. 2009, 34, 1955–1961. [Google Scholar] [CrossRef] [PubMed]
  52. Deng, S.; West, B.J. Antidepressant effects of noni fruit and its active principals. Asian. J. Med. Sci. 2011, 3, 79–83. [Google Scholar]
  53. Ryu, S.Y.; Han, Y.N.; Han, B.H. Monoamine oxidase-A inhibitors from medicinal plants. Arch. Pharm. Res. 1988, 11, 230–239. [Google Scholar] [CrossRef]
  54. Olsen, H.T.; Stafford, G.I.; van Staden, J.; Christensen, S.B.; Jäger, A.K. Isolation of the MAO-inhibitor naringenin from Mentha aquatica L. J. Ethnopharmacol. 2008, 117, 500–502. [Google Scholar] [CrossRef] [PubMed]
  55. Haraguchi, H.; Tanaka, Y.; Kabbash, A.; Fujioka, T.; Ishizu, T.; Yagi, A. Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry 2004, 65, 2255–2260. [Google Scholar] [CrossRef] [PubMed]
  56. Dreiseitel, A.; Korte, G.; Schreier, P.; Oehme, A.; Locher, S.; Domani, M.; Hajak, G.; Sand, P.G. Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B. Pharmacol. Res. 2009, 59, 306–311. [Google Scholar] [CrossRef] [PubMed]
  57. Han, X.H.; Hong, S.S.; Hwang, J.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from Cayratia japonica. Arch. Pharm. Res. 2007, 30, 13–70. [Google Scholar] [CrossRef] [PubMed]
  58. Han, Y.N.; Noh, D.B.; Han, D.S. Studies on the monoamine oxidase inhibitors of medicinal plants I. Isolation of MAO-B inhibitors from Chrysanthemum indicum. Arch. Pharm. Res. 1987, 10, 142–147. [Google Scholar] [CrossRef]
  59. Gao, G.Y.; Li, D.J.; Keung, W.M. Synthesis of potential antidipsotropic isoflavones: Inhibitors of the mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway. J. Med. Chem. 2001, 44, 3320–3328. [Google Scholar] [CrossRef] [PubMed]
  60. Ji, H.F.; Zhang, H.Y. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer’s disease. J. Mol. Struct. Theochem. 2006, 767, 3–9. [Google Scholar] [CrossRef]
  61. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739–1749. [Google Scholar] [CrossRef] [PubMed]
  62. Greeson, J.M.; Sanford, B.; Monti, D.A. St. John’s wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 2001, 153, 402–414. [Google Scholar] [CrossRef] [PubMed]
  63. Gao, L.; Fang, J.S.; Bai, X.Y.; Zhou, D.; Wang, Y.T.; Liu, A.L.; Du, G.H. In silico Target Fishing for the Potential Targets and Molecular Mechanisms of Baicalein as an Antiparkinsonian Agent: Discovery of the Protective Effects on NMDA Receptor-Mediated Neurotoxicity. Chem. Biol. Drug. Des. 2013, 81, 675–687. [Google Scholar] [CrossRef] [PubMed]
  64. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Beula, S.J.; Raj, V.B.; Mathew, B. Isolation and molecular recognization of 6-prenyl apigenin towards MAO-A as the active principle of seeds of Achyranthes aspera. Biomed. Prev. Nutr. 2014, 4, 379–382. [Google Scholar] [CrossRef]
  66. Gidaro, M.C.; Astorino, C.; Petzer, A.; Carradori, S.; Alcaro, F.; Costa, G.; Artese, A.; Rafele, G.; Russo, F.M.; Petzer, J.P.; et al. Kaempferol as selective human MAO-A inhibitor: analytical detection in calabrian red wines, biological and molecular modeling studies. J. Agric. Food Chem. 2016, 64, 1394–1400. [Google Scholar] [CrossRef] [PubMed]
  67. Chimenti, F.; Cottiglia, F.; Bonsignore, L.; Casu, L.; Casu, M.; Floris, C.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; et al. Quercetin as the Active Principle of Hypericum h ircinum Exerts a Selective Inhibitory Activity against MAO-A: Extraction, Biological Analysis, and Computational Study. J. Nat. Prod. 2006, 69, 945–949. [Google Scholar] [CrossRef] [PubMed]
  68. Jo, G.; Sung, S.H.; Lee, Y.; Kim, B.G.; Yoon, J.; Lee, H.O.; Ji, S.Y.; Koh, D.; Ahn, J.H.; Lim, Y. Discovery of Monoamine Oxidase A Inhibitors Derived from in silico Docking. Bull. Korean. Chem. Soc. 2012, 33, 3841–3844. [Google Scholar] [CrossRef]
  69. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470–489. [Google Scholar] [CrossRef]
  70. Desideri, N.; Bolasco, A.; Fioravanti, R.; Proietti, M.L.; Orallo, F.; Yáñez, M.; Ortuso, F.; Alcaro, S. Homoisoflavonoids: Natural scaffolds with potent and selective monoamine oxidase-B inhibition properties. J. Med. Chem. 2011, 54, 2155–2164. [Google Scholar] [CrossRef]
  71. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.; et al. A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg. Med. Chem. 2010, 18, 1273–1279. [Google Scholar] [CrossRef] [PubMed]
  72. Turkmenoglu, F.P.; Baysal, İ.; Ciftci-Yabanoglu, S.; Yelekci, K.; Temel, H.; Paşa, S.; Ezer, N.; Çalış, İ.; Ucar, G. Flavonoids from Sideritis species: Human monoamine oxidase (hMAO) inhibitory activities, molecular docking studies and crystal structure of xanthomicrol. Molecules 2015, 20, 7454–7473. [Google Scholar] [CrossRef] [PubMed]
  73. Sivaraman, D.; Vignesh, G.; Selvaraj, R.; Dare, B.J. Identification of potential monoamine oxidase inhibitor from herbal source for the treatment of major depressive disorder: An in-silico screening approach. Der. Pharma. Chemica. 2015, 7, 224–234. [Google Scholar]
  74. Zarmouh, N.; Eyunni, S.; Mazzio, E.; Messeha, S.; Elshami, F.; Soliman, K. Bavachinin and Genistein, Two Novel Human Monoamine Oxidase-B (MAO-B) Inhibitors in the Psoralea Corylifolia Seeds. FASEB J. 2015, 29, 771–772. [Google Scholar]
  75. Zarmouh, N.O.; Mazzio, E.A.; Elshami, F.M.; Messeha, S.S.; Eyunni, S.V.; Soliman, K.F. Evaluation of the inhibitory effects of bavachinin and bavachin on human monoamine oxidases A and B. Evid. Based. Complement. Alternat. Med. 2015, 1–14. [Google Scholar] [CrossRef] [PubMed]
  76. Zarmouh, N.O.; Messeha, S.S.; Elshami, F.M.; Soliman, K.F. Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and-B Inhibitor. Evid. Based. Complement. Alternat. Med. 2016, 1–12. [Google Scholar] [CrossRef] [PubMed]
Molecules 24 00418 g001 550
Figure 1. Quercetin.
Figure 1. Quercetin.
Molecules 24 00418 g001
Molecules 24 00418 g002 550
Figure 2. Structures of Formononetin (1) and Kushenol F (2).
Figure 2. Structures of Formononetin (1) and Kushenol F (2).
Molecules 24 00418 g002
Molecules 24 00418 g003 550
Figure 3. Structures of isolated constituents from Banisteriopsis caapi.
Figure 3. Structures of isolated constituents from Banisteriopsis caapi.
Molecules 24 00418 g003
Molecules 24 00418 g004 550
Figure 4. Flavanoids structures description.
Figure 4. Flavanoids structures description.
Molecules 24 00418 g004
Molecules 24 00418 g005 550
Figure 5. Cynaroside.
Figure 5. Cynaroside.
Molecules 24 00418 g005
Molecules 24 00418 g006 550
Figure 6. Liquiritigenin.
Figure 6. Liquiritigenin.
Molecules 24 00418 g006
Molecules 24 00418 g007 550
Figure 7. Structures of flavonoids.
Figure 7. Structures of flavonoids.
Molecules 24 00418 g007
Molecules 24 00418 g008 550
Figure 8. Epigallocatechin gallate.
Figure 8. Epigallocatechin gallate.
Molecules 24 00418 g008
Molecules 24 00418 g009 550
Figure 9. Structure description of myricetin galloylglycosides.
Figure 9. Structure description of myricetin galloylglycosides.
Molecules 24 00418 g009
Molecules 24 00418 g010 550
Figure 10. Kaempferol.
Figure 10. Kaempferol.
Molecules 24 00418 g010
Molecules 24 00418 g011 550
Figure 11. Genistein.
Figure 11. Genistein.
Molecules 24 00418 g011
Molecules 24 00418 g012 550
Figure 12. Naringenin.
Figure 12. Naringenin.
Molecules 24 00418 g012
Molecules 24 00418 g013 550
Figure 13. Structures of 5-hydroxyflavanone (3) and 2-methoxy-3-(1-dimethylallyl)-6a,10a-dihydrobenzo(1,2-c)chroman-6-one (4).
Figure 13. Structures of 5-hydroxyflavanone (3) and 2-methoxy-3-(1-dimethylallyl)-6a,10a-dihydrobenzo(1,2-c)chroman-6-one (4).
Molecules 24 00418 g013
Molecules 24 00418 g014 550
Figure 14. Chemical structures of isoflavone daidzein and its various analogs.
Figure 14. Chemical structures of isoflavone daidzein and its various analogs.
Molecules 24 00418 g014
Molecules 24 00418 g015 550
Figure 15. 3-(4-methoxyphenyl)-1H-benzo[f]chromen-1-one
Figure 15. 3-(4-methoxyphenyl)-1H-benzo[f]chromen-1-one
Molecules 24 00418 g015
Molecules 24 00418 g016 550
Figure 16. (E)-3-(4-(Dimethylamino)benzylidene)chroman-4-one.
Figure 16. (E)-3-(4-(Dimethylamino)benzylidene)chroman-4-one.
Molecules 24 00418 g016
Molecules 24 00418 g017 550
Figure 17. (E)-5,7-dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one.
Figure 17. (E)-5,7-dihydroxy-3-(4-hydroxybenzylidene)chroman-4-one.
Molecules 24 00418 g017
Molecules 24 00418 g018 550
Figure 18. 6-Prenyl apigenin.
Figure 18. 6-Prenyl apigenin.
Molecules 24 00418 g018
Molecules 24 00418 g019 550
Figure 19. Structure-activity relationships (SAR) trends inferred from the data of enzymatic and docking experiments reported above.
Figure 19. Structure-activity relationships (SAR) trends inferred from the data of enzymatic and docking experiments reported above.
Molecules 24 00418 g019
Table
Table 1. Docking profile of natural flavonoids with target protein and interactions.
Table 1. Docking profile of natural flavonoids with target protein and interactions.
FlavonoidsTarget ProteinImportant Amino Acid Residues CommentsSoftwareReferences
QuercetinMAO-A PDB (2Z5X)Tyr444, Tyr197, and Asn181Quercetin fitted well within the hMAO-A active site than in the hMAO-B active site due to development of highest π-π interaction and intermolecular hydrogen bonds.Schrodinger [61]Zhang et al. [62]
BaicaleinMAO-B PDB (2Z5Y)Leu164 and Leu167Two catecholic OH groups of baicalein showed hydrogen bonding with Leu167and Leu164 respectively.Schrodinger [61]Gao et al. [63]
6-prenyl apigeninhMAO-A PDB (2Z5X)Tyr 444 and Tyr4076-prenyl apigenin the structural shared π electrons of the hydroxyl groups were sandwiched between phenolic side chains of TYR407 and TYR 444 composed the ‘aromatic cage’ of the hydrophobic pocket of the enzyme.AutoDock [64]Beula et al. [65]
KaempferolhMAO-A PDB (2Z5X)Ile335 of hMAO-A Tyr326 of hMAO-B Kaempferol in the dynamic site of hMAO-A established hydrophobic interactions with important residues of hMAO-A for a longer time than in the hMAO-B pocket.Schrödinger [61]Gidaro et al. [66]
Table
Table 2. Docking profile of natural flavonoids from Sideritis, against MAO-A PDB (2Z5X) and MAO-B PDB (2XFU) with docking score and free binding energy (ΔG) and Ki (μM).
Table 2. Docking profile of natural flavonoids from Sideritis, against MAO-A PDB (2Z5X) and MAO-B PDB (2XFU) with docking score and free binding energy (ΔG) and Ki (μM).
Sr. NoFlavonoidBinding Score Energy Value for MAO-A (Kcal/mol)Calculated Ki for MAO-A (μM)Binding Score Energy Value for MAO-B (Kcal/mol)Calculated Ki for MAO-B (μM)
1Isoscutellarein 7-O-[6′′′-O-acetyl-β-d-allopyranosyl-(1→2)]-6″-O-acetyl-β-d-glucopyranoside−3.811660.008.92-
2Salvigenin−8.300.867−7.513.63
3Isoscutellarein 7-O-[6′′′-O-acetyl-β-d-allopyranosyl-(1→2)]-β-d-glucopyranoside−4.15930.105.79-
4Xanthomicrol−7.801.90−5.7864.26
Table
Table 3. Natural flavonoids docked against MAO-A PDB (2Z5X) showing docking score and free binding free energy (Kcal/mol) and inhibition constant Ki (µM) with no. of hydrogen bonds along with interacting amino acid residues.
Table 3. Natural flavonoids docked against MAO-A PDB (2Z5X) showing docking score and free binding free energy (Kcal/mol) and inhibition constant Ki (µM) with no. of hydrogen bonds along with interacting amino acid residues.
Sr. NoName of the LeadBinding Free Energy (Kcal/mol)Inhibition Constant Ki (µM)No. of Hydrogen BondsInteracting Amino Acid Residue
1Kaempferol−5.174.6312397 TRP, 352 PHE, 406 CYS, 444 TYR, 448 ALA, 303 VAL, 51ARG, 407 TYR, 52 THR, 435 THR, 305 LYS, 445 MET
2Quercetin−4.40636.609436 GLU, 448 ALA, 52 THR, 435 THR, 407 TYR,51 ARG, 406 CYS, 23 ILE, 445 MET
3Apigenin−7.652.618305 LYS, 397 TRP, 448 ALA, 51 ARG, 406 CYS, 435 THR, 352 PHE, 407 TYR
4Luteolin−7.672.4211448 ALA, 23 ILE, 435 THR, 406 CYS, 303 VAL, 52 THR, 51 ARG, 397 TRP, 445 MET, 407 TYR,444TYR
5Brofaromine (Standard)−7.553.0610303 VAL, 397 TRP, 51 ARG, 52 THR, 406 CYS, 305 LYS, 445 MET, 407 TYR, 435 THR, 448 ALA
Table
Table 4. Inhibition affinity by docking studies, of MAO isoforms by flavanones of Psoralea corylifolia extract.
Table 4. Inhibition affinity by docking studies, of MAO isoforms by flavanones of Psoralea corylifolia extract.
Sr. NoNatural LigandsMAO-A Active Site PDB (2BXR)MAO-B Active Site PDB (1GOS)Overall Bonds MAO Inhibition Selectivity
Docking Score Predicted H-BondDocking ScorePredicted H-BondH-Bond Active Site Residue
1.Bavachinin−1.060−6.822OH⋯O HO⋯HNTHR:201: A THR:201: AB
3Safinamide−0.220−6.123NH⋯O NH⋯O NH⋯OGLU:84: A THR:201: A PRO:102: AB
4Bavachin−8.72H2O-726−3.950⋯⋯NA
Table
Table 5. Docking scores of isoflavone genistein and daidzein within human monoamine oxidase-A and -B binding sites.
Table 5. Docking scores of isoflavone genistein and daidzein within human monoamine oxidase-A and -B binding sites.
Sr. NoName of the LeadMAO-AMAO-BRMSD ÅAmino Acid
Docking ScorePredicted H-BondDocking ScorePredicted H-Bond
1Genistein (GST)−7.00−12.82 (OH⋅ ⋅ ⋅ N)2.27THR: 201: A
2Daidzein (DZ)−6.90−12.81 (O⋅ ⋅ ⋅ HN)2.32THR: 201: A
Table
Table 6. Summary of the molecular docking studies and inhibitory activity of compounds against MAO-A and MAO-B enzymes.
Table 6. Summary of the molecular docking studies and inhibitory activity of compounds against MAO-A and MAO-B enzymes.
Sr. NoName of the LeadhMAO-BhMAO-A
IC50 (μM)ΔG Bind (Kcal/mol)IC50 (μM)ΔG Bind (Kcal/mol)
1Kaempferol>100−42.660.525 ± 0.035−49.52
2Quercetin>100−46.983.98 ± 0.265−48.35
3Harmine--0.029 ± 0.0042−46.07
4Safinamide0.0479 ± 0.00472−73.70--

Share and Cite

MDPI and ACS Style

Dhiman, P.; Malik, N.; Sobarzo-Sánchez, E.; Uriarte, E.; Khatkar, A. Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders. Molecules 2019, 24, 418. https://doi.org/10.3390/molecules24030418

AMA Style

Dhiman P, Malik N, Sobarzo-Sánchez E, Uriarte E, Khatkar A. Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders. Molecules. 2019; 24(3):418. https://doi.org/10.3390/molecules24030418

Chicago/Turabian Style

Dhiman, Priyanka, Neelam Malik, Eduardo Sobarzo-Sánchez, Eugenio Uriarte, and Anurag Khatkar. 2019. "Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders" Molecules 24, no. 3: 418. https://doi.org/10.3390/molecules24030418

Article Metrics

Back to TopTop